Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 gene expression, and plasma ACE2 levels: a Mendelian randomization study

Dipender Gill, Marios Arvanitis, Paul Carter, Ana I. Hernández Cordero, Brian Jo, Ville Karhunen, View ORCID ProfileSusanna C. Larsson, Xuan Li, Sam M. Lockhart, Amy Mason, Evanthia Pashos, Ashis Saha, Vanessa Y. Tan, View ORCID ProfileVerena Zuber, Yohan Bossé, Sarah Fahle, Ke Hao, Tao Jiang, Philippe Joubert, Alan C. Lunt, Willem Hendrik Ouwehand, David J. Roberts, Wim Timens, Maarten van den Berge, Nicholas A. Watkins, Alexis Battle, Adam S. Butterworth, John Danesh, Barbara E. Engelhardt, James E. Peters, Don D. Sin, Stephen Burgess
doi: https://doi.org/10.1101/2020.04.10.20059121
Dipender Gill
1Department of Epidemiology and Biostatistics, Medical School Building, St Mary’s Hospital, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dipender.gill@imperial.ac.uk
Marios Arvanitis
2Department of Medicine, Division of Cardiology, Johns Hopkins University, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Carter
3Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana I. Hernández Cordero
4The University of British Columbia Centre for Heart Lung Innovation, St Paul’s Hospital, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Jo
5Program in Quantitative and Computational Biology, Lewis Sigler Institute for Integrative Biology, Princeton, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ville Karhunen
1Department of Epidemiology and Biostatistics, Medical School Building, St Mary’s Hospital, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanna C. Larsson
6Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
7Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Susanna C. Larsson
Xuan Li
4The University of British Columbia Centre for Heart Lung Innovation, St Paul’s Hospital, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sam M. Lockhart
8Medical Research Council Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Mason
9British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
10National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evanthia Pashos
11Internal Medicine Research Unit, Pfizer Worldwide Research, Development & Medical, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashis Saha
12Department of Computer Science, Johns Hopkins University, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanessa Y. Tan
13Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK
14Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Verena Zuber
1Department of Epidemiology and Biostatistics, Medical School Building, St Mary’s Hospital, Imperial College London, London, UK
15Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Verena Zuber
Yohan Bossé
16Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Fahle
9British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
10National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, UK
17National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ke Hao
18Department of Genetics and Genomic Sciences, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tao Jiang
9British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Joubert
16Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan C. Lunt
1Department of Epidemiology and Biostatistics, Medical School Building, St Mary’s Hospital, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Willem Hendrik Ouwehand
20NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge, UK
21Wellcome Sanger Institute, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Roberts
17National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, UK
22NHS Blood and Transplant-Oxford Centre, Level 2, John Radcliffe Hospital, Oxford, UK
23Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wim Timens
24University of Groningen, Department of Pathology and Medical Biology and Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maarten van den Berge
25University of Groningen, Department of Pulmonology and Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas A. Watkins
17National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, UK
26Research and Development, NHS Blood and Transplant, Bristol, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexis Battle
27Department of Biomedical Engineering and Center for Computational Biology, Johns Hopkins University, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam S. Butterworth
9British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
10National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, UK
17National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, UK
28British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK
29Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Danesh
9British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
10National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, UK
17National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, UK
21Wellcome Sanger Institute, Cambridge, UK
28British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK
29Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara E. Engelhardt
30Computer Science Department and Center for Statistics and Machine Learning, Princeton University, Princeton, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James E. Peters
29Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK
31Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Don D. Sin
4The University of British Columbia Centre for Heart Lung Innovation, St Paul’s Hospital, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Burgess
9British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
10National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, UK
15Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK
28British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK
32Homerton College, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sb452@medschl.cam.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives To use human genetic variants that proxy angiotensin-converting enzyme (ACE) inhibitor drug effects and cardiovascular risk factors to provide insight into how these exposures affect lung ACE2 and TMPRSS2 gene expression and circulating ACE2 levels.

Design Two-sample Mendelian randomization (MR) analysis.

Setting Summary-level genetic association data.

Participants Participants were predominantly of European ancestry. Variants that proxy ACE inhibitor drug effects and cardiometabolic risk factors (body mass index, chronic obstructive pulmonary disease, lifetime smoking index, low-density lipoprotein cholesterol, systolic blood pressure and type 2 diabetes mellitus) were selected from publicly available genome-wide association study data (sample sizes ranging from 188,577 to 898,130 participants). Genetic association estimates for lung expression of ACE2 and TMPRSS2 were obtained from the Gene-Tissue Expression (GTEx) project (515 participants) and the Lung eQTL Consortium (1,038 participants). Genetic association estimates for circulating plasma ACE2 levels were obtained from the INTERVAL study (4,947 participants).

Main outcomes and measures Lung ACE2 and TMPRSS2 expression and plasma ACE2 levels.

Results There were no association of genetically proxied ACE inhibition with any of the outcomes considered here. There was evidence of a positive association of genetic liability to type 2 diabetes mellitus with lung ACE2 gene expression in GTEx (p = 4×10−4) and with circulating plasma ACE2 levels in INTERVAL (p = 0.03), but not with lung ACE2 expression in the Lung eQTL Consortium study (p = 0.68). There were no associations between genetically predicted levels of the other cardiometabolic traits with the outcomes.

Conclusions This study does not provide evidence to support that ACE inhibitor antihypertensive drugs affect lung ACE2 and TMPRSS2 expression or plasma ACE2 levels. In the current COVID-19 pandemic, our findings do not support a change in ACE inhibitor medication use without clinical justification.

What is already known on this topic

  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

  • Serine protease TMPRSS2 is involved in priming the SARS-CoV-2 spike protein for cellular entry through the angiotensin-converting enzyme 2 (ACE2) receptor.

  • Expression of ACE2 and TMPRSS2 in the lung epithelium might have implications for risk of SARS-CoV-2 infection and severity of COVID-19.

What this study adds

  • We used human genetic variants that proxy ACE inhibitor drug effects and cardiometabolic risk factors to provide insight into how these exposures affect lung ACE2 and TMPRSS2 expression and circulating ACE2 levels.

  • Our findings do not support the hypothesis that ACE inhibitors have effects on ACE2 expression.

  • We found some support for an association of genetic liability to type 2 diabetes mellitus with higher lung ACE2 expression and plasma ACE2 levels, but evidence was inconsistent across studies.

Competing Interest Statement

All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: DG is a part-time employee of Novo Nordisk. ASB has received grants outside of this work from AstraZeneca, Biogen, BioMarin, Bioverativ, Merck and Novartis and personal fees from Novartis. BEE is on the scientific advisory boards of Freenome and Celsius Therapeutics, and is a full time employee at Genomics plc while on a leave of absence from Princeton University. JEP has received travel and accommodation expenses and hospitality from Olink to speak at Olink-sponsored academic meetings. EP is a full-time employee of Pfizer. JD sits on advisory boards for Novartis, Sanofi, and Astra Zeneca. All other authors have no conflicts of interest to declare.

Funding Statement

DG is supported by the Wellcome 4i Program at Imperial College London (award number 203928/Z/16/Z). SB is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (award number 204623/Z/16/Z). The academic coordinating centre for INTERVAL at Cambridge University was supported by core funding from: NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024), UK Medical Research Council (MR/L003120/1), British Heart Foundation (SP/09/002; RG/13/13/30194; RG/18/13/33946) and the NIHR (Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust), and Health Data Research UK. SF is funded by the NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024). JD holds a British Heart Foundation Personal Chair and a National Institute for Health Research Senior Investigator Award. SL is funded by the Swedish Heart-Lung Foundation, the Swedish Research Council, and the Swedish Research Council for Health, Working Life and Welfare. VK is funded by a European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant (721567). VYT is supported by the Cancer Research UK (CRUK) Integrative Cancer Epidemiology Programme (C18281/A19169). SML is supported by an Academic Clinical Fellowship from the NIHR. YB holds a Canada Research Chair in Genomics of Heart and Lung Diseases. JEP is supported by a UKRI Innovation Fellowship at Health Data Research UK (MR/S004068/1). This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and the Wellcome Trust.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Competing interest statement: All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: DG is a part-time employee of Novo Nordisk. ASB has received grants outside of this work from AstraZeneca, Biogen, BioMarin, Bioverativ, Merck and Novartis and personal fees from Novartis. BEE is on the scientific advisory boards of Freenome and Celsius Therapeutics, and is a full time employee at Genomics plc while on a leave of absence from Princeton University. JEP has received travel and accommodation expenses and hospitality from Olink to speak at Olink-sponsored academic meetings. EP is a full-time employee of Pfizer. JD sits on advisory boards for Novartis, Sanofi, and Astra Zeneca. All other authors have no conflicts of interest to declare.

  • Transparency declaration: The corresponding authors affirm that the manuscript is an honest, accurate, and transparent account of the research being reported, and that no important aspects of the study have been omitted.

  • Dissemination declaration: This work uses genetic association summary data from published studies and dissemination to the participants that contributed these data is therefore not possible.

  • Copyright: The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJPGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence.

  • Funding: DG is supported by the Wellcome 4i Program at Imperial College London (award number 203928/Z/16/Z). SB is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (award number 204623/Z/16/Z). The academic coordinating centre for INTERVAL at Cambridge University was supported by core funding from: NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024), UK Medical Research Council (MR/L003120/1), British Heart Foundation (SP/09/002; RG/13/13/30194; RG/18/13/33946) and the NIHR (Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust), and Health Data Research UK. SF is funded by the NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024). JD holds a British Heart Foundation Personal Chair and a National Institute for Health Research Senior Investigator Award. SL is funded by the Swedish Heart-Lung Foundation, the Swedish Research Council, and the Swedish Research Council for Health, Working Life and Welfare. VK is funded by a European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant (721567). VYT is supported by the Cancer Research UK (CRUK) Integrative Cancer Epidemiology Programme (C18281/A19169). SML is supported by an Academic Clinical Fellowship from the NIHR. YB holds a Canada Research Chair in Genomics of Heart and Lung Diseases. JEP is supported by a UKRI Innovation Fellowship at Health Data Research UK (MR/S004068/1). This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and the Wellcome Trust.

Data Availability

The data used in this work are obtained from published studies that obtained relevant participant consent and ethical approval. All variants used as instruments and their genetic association estimates were selected from publicly available data sources, and are provided in Supplementary Tables 1-8. GWAS summary data for all the outcomes considered in this study are publicly available at http://dx.doi.org/10.6084/m9.figshare.12102681 (GTEx), http://dx.doi.org/10.6084/m9.figshare.12102711 (Lung eQTL Consortium), and http://dx.doi.org/10.6084/m9.figshare.12102777 (INTERVAL).

http://dx.doi.org/10.6084/m9.figshare.12102681

http://dx.doi.org/10.6084/m9.figshare.12102711

http://dx.doi.org/10.6084/m9.figshare.12102777

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted April 14, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 gene expression, and plasma ACE2 levels: a Mendelian randomization study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 gene expression, and plasma ACE2 levels: a Mendelian randomization study
Dipender Gill, Marios Arvanitis, Paul Carter, Ana I. Hernández Cordero, Brian Jo, Ville Karhunen, Susanna C. Larsson, Xuan Li, Sam M. Lockhart, Amy Mason, Evanthia Pashos, Ashis Saha, Vanessa Y. Tan, Verena Zuber, Yohan Bossé, Sarah Fahle, Ke Hao, Tao Jiang, Philippe Joubert, Alan C. Lunt, Willem Hendrik Ouwehand, David J. Roberts, Wim Timens, Maarten van den Berge, Nicholas A. Watkins, Alexis Battle, Adam S. Butterworth, John Danesh, Barbara E. Engelhardt, James E. Peters, Don D. Sin, Stephen Burgess
medRxiv 2020.04.10.20059121; doi: https://doi.org/10.1101/2020.04.10.20059121
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 gene expression, and plasma ACE2 levels: a Mendelian randomization study
Dipender Gill, Marios Arvanitis, Paul Carter, Ana I. Hernández Cordero, Brian Jo, Ville Karhunen, Susanna C. Larsson, Xuan Li, Sam M. Lockhart, Amy Mason, Evanthia Pashos, Ashis Saha, Vanessa Y. Tan, Verena Zuber, Yohan Bossé, Sarah Fahle, Ke Hao, Tao Jiang, Philippe Joubert, Alan C. Lunt, Willem Hendrik Ouwehand, David J. Roberts, Wim Timens, Maarten van den Berge, Nicholas A. Watkins, Alexis Battle, Adam S. Butterworth, John Danesh, Barbara E. Engelhardt, James E. Peters, Don D. Sin, Stephen Burgess
medRxiv 2020.04.10.20059121; doi: https://doi.org/10.1101/2020.04.10.20059121

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (50)
  • Cardiovascular Medicine (450)
  • Dentistry and Oral Medicine (82)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5247)
  • Forensic Medicine (3)
  • Gastroenterology (195)
  • Genetic and Genomic Medicine (755)
  • Geriatric Medicine (80)
  • Health Economics (212)
  • Health Informatics (696)
  • Health Policy (356)
  • Health Systems and Quality Improvement (223)
  • Hematology (99)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5848)
  • Intensive Care and Critical Care Medicine (358)
  • Medical Education (103)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (762)
  • Nursing (43)
  • Nutrition (130)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (476)
  • Ophthalmology (150)
  • Orthopedics (38)
  • Otolaryngology (95)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (140)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (859)
  • Public and Global Health (2004)
  • Radiology and Imaging (348)
  • Rehabilitation Medicine and Physical Therapy (158)
  • Respiratory Medicine (283)
  • Rheumatology (94)
  • Sexual and Reproductive Health (73)
  • Sports Medicine (76)
  • Surgery (109)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)